Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.
| Revenue (Most Recent Fiscal Year) | $52.74M |
| Net Income (Most Recent Fiscal Year) | $-6.60M |
| PE Ratio (Current Year Earnings Estimate) | 11.77 |
| PE Ratio (Trailing 12 Months) | 11.26 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 29.10% |
| Net Margin (Trailing 12 Months) | 23.50% |
| Return on Equity (Trailing 12 Months) | 31.60% |
| Return on Assets (Trailing 12 Months) | 20.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.91 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.89 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.23 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 80.57M |
| Free Float | 75.17M |
| Market Capitalization | $208.68M |
| Average Volume (Last 20 Days) | 0.79M |
| Beta (Past 60 Months) | 0.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |